Patients using non-COX-2 inhibitors for >28 days and COX-2 along with non-COX-2 inhibitors for >90 days had a lower incidence of second cancer, with adjusted SHR of 0.62 (95% CI 0.40–0.95) and 0.24 (95% CI 0.09–0.61), respectively. The gene discussed is PTGS2; the disease is cancer.